Full Press Release Details
GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in the following upcoming investor conferences:
A webcast of the fireside chats will be available via the Events section of the Altimmune website.
About Altimmune Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company’s lead investigational candidate, pemvidutide, is a unique dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com .
Follow @Altimmune, Inc. on LinkedIn Follow @AltimmuneInc on X
Investor Contact: Luis Sanay, CFA Vice President, Investor Relations ir@altimmune.com
Media Contact: Real Chemistry altimmune@realchemistry.com